Floatz logo

Avelumab

Microsatellite Instability

ImmunityBio, Inc.monoclonal_antibodyPhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Microsatellite Instability cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Fate Therapeutics
Phase 2B
Nivolumab
Fate Therapeutics
Phase 2B
Cyclophosphamide
Udai Kammula
Phase 2B
Atezolizumab
Fate Therapeutics
Phase 2B
Fludarabine
Udai Kammula
Phase 2B

View all 14 →

Same molecule, other indications

Avelumab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
urothelial carcinomaDormant
B
Indicative ·
58 / 100
View asset →
bladder transitional cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →